AU772703B2 - A method for the transfer of antigens to dendritic cells - Google Patents

A method for the transfer of antigens to dendritic cells Download PDF

Info

Publication number: AU772703B2
Authority: AU; Australia
Prior art keywords: cells; antigen; dcs; antigens; dendritic cells
Prior art date: 1999-05-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU52159/00A

Other languages

English (en)

Other versions

AU5215900A (en

Inventor

Claudio Bordignon

Vincenzo Russo

Catia Traversari

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genera SpA

Original Assignee

Genera SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-28

Filing date

2000-05-24

Publication date

2004-05-06

2000-05-24 Application filed by Genera SpA filed Critical Genera SpA

2000-12-18 Publication of AU5215900A publication Critical patent/AU5215900A/en

2004-05-06 Application granted granted Critical

2004-05-06 Publication of AU772703B2 publication Critical patent/AU772703B2/en

2020-05-24 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

210000004443 dendritic cell Anatomy 0.000 title claims description 75
239000000427 antigen Substances 0.000 title claims description 55
108091007433 antigens Proteins 0.000 title claims description 55
102000036639 antigens Human genes 0.000 title claims description 54
238000000034 method Methods 0.000 title claims description 24
238000012546 transfer Methods 0.000 title claims description 14
210000004027 cell Anatomy 0.000 claims description 59
206010028980 Neoplasm Diseases 0.000 claims description 21
239000003550 marker Substances 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 5
208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
210000002950 fibroblast Anatomy 0.000 claims description 4
208000024908 graft versus host disease Diseases 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
102000004127 Cytokines Human genes 0.000 claims description 3
108090000695 Cytokines Proteins 0.000 claims description 3
230000006907 apoptotic process Effects 0.000 claims description 3
238000009169 immunotherapy Methods 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 2
230000001404 mediated effect Effects 0.000 claims 1
239000013598 vector Substances 0.000 description 15
238000004806 packaging method and process Methods 0.000 description 10
230000000638 stimulation Effects 0.000 description 9
238000010361 transduction Methods 0.000 description 9
230000026683 transduction Effects 0.000 description 9
230000014509 gene expression Effects 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
230000001177 retroviral effect Effects 0.000 description 6
238000001890 transfection Methods 0.000 description 6
108700019146 Transgenes Proteins 0.000 description 4
230000001640 apoptogenic effect Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
108010002634 HLA-Bw4 antigen Proteins 0.000 description 3
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
108010025815 Kanamycin Kinase Proteins 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000004624 confocal microscopy Methods 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000004044 response Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
108010039471 Fas Ligand Protein Proteins 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
229920000209 Hexadimethrine bromide Polymers 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
102000000440 Melanoma-associated antigen Human genes 0.000 description 2
108050008953 Melanoma-associated antigen Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
102000009270 Tumour necrosis factor alpha Human genes 0.000 description 2
108050000101 Tumour necrosis factor alpha Proteins 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000000139 costimulatory effect Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000002101 lytic effect Effects 0.000 description 2
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000000861 pro-apoptotic effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102000000412 Annexin Human genes 0.000 description 1
108050008874 Annexin Proteins 0.000 description 1
108091067183 BAGE family Proteins 0.000 description 1
102000039506 BAGE family Human genes 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
102000025850 HLA-A2 Antigen Human genes 0.000 description 1
108010074032 HLA-A2 Antigen Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010010995 MART-1 Antigen Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
108010008707 Mucin-1 Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000005809 anti-tumor immunity Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000007402 cytotoxic response Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
230000010039 intracellular degradation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
210000004296 naive t lymphocyte Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4277—Fusion proteins originating from gene translocation in cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Mycology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AU52159/00A 1999-05-28 2000-05-24 A method for the transfer of antigens to dendritic cells Ceased AU772703B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IT1999MI001180A IT1312570B1 (it)	1999-05-28	1999-05-28	Metodo per il traferimento di antigeni a cellule dendritiche.
ITMI99A001180		1999-05-28
PCT/EP2000/004712 WO2000073415A2 (fr)	1999-05-28	2000-05-24	Method de transfert d'antigenes dans des cellules dendritiques

Publications (2)

Publication Number	Publication Date
AU5215900A AU5215900A (en)	2000-12-18
AU772703B2 true AU772703B2 (en)	2004-05-06

Family

ID=11383060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU52159/00A Ceased AU772703B2 (en)	1999-05-28	2000-05-24	A method for the transfer of antigens to dendritic cells

Country Status (10)

Country	Link
EP (1)	EP1185626A2 (fr)
JP (1)	JP2003501019A (fr)
KR (1)	KR20020013563A (fr)
CN (1)	CN1187442C (fr)
AU (1)	AU772703B2 (fr)
CA (1)	CA2375349A1 (fr)
HK (1)	HK1047131A1 (fr)
IL (1)	IL146777A0 (fr)
IT (1)	IT1312570B1 (fr)
WO (1)	WO2000073415A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6506596B2 (en)	2000-06-01	2003-01-14	Anna-Lena Spetz-Holmgren	Method of DNA transfer
CN100392074C (zh) *	2003-10-15	2008-06-04	上海海欣生物技术有限公司	树突状细胞肿瘤疫苗及其制法和用途
KR20160045151A (ko) *	2005-04-08	2016-04-26	아르고스 쎄라퓨틱스 인코포레이티드	수지상 세포 조성물 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995034638A1 (fr) *	1994-06-14	1995-12-21	The Board Of Trustees Of Leland Stanford Junior University	Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques
WO1999042564A2 (fr) *	1998-02-20	1999-08-26	The Rockefeller University	Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1261847B (it) *	1993-09-01	1996-06-03	San Romanello Centro Fond	Metodo per marcare cellule eucariote.
US5871728A (en) *	1995-03-31	1999-02-16	University Of Pittsburgh	Method of regulating dendritic cell maturation
ES2232845T3 (es) *	1997-08-22	2005-06-01	Science Park Raf S.P.A.	Vacunacion tumoral mediante la utilizacion de celulas autologas o celulas presentadoras de antigeno (apc) relacionadas con hla transducidas con un antigeno tumoral y un antigeno ajeno capaz de producir una reaccion inmune.

1999
- 1999-05-28 IT IT1999MI001180A patent/IT1312570B1/it active
2000
- 2000-05-24 HK HK02108610.1A patent/HK1047131A1/zh unknown
- 2000-05-24 WO PCT/EP2000/004712 patent/WO2000073415A2/fr not_active Ceased
- 2000-05-24 EP EP00936788A patent/EP1185626A2/fr not_active Withdrawn
- 2000-05-24 AU AU52159/00A patent/AU772703B2/en not_active Ceased
- 2000-05-24 IL IL14677700A patent/IL146777A0/xx unknown
- 2000-05-24 CA CA002375349A patent/CA2375349A1/fr not_active Abandoned
- 2000-05-24 KR KR1020017015173A patent/KR20020013563A/ko not_active Withdrawn
- 2000-05-24 CN CNB008081557A patent/CN1187442C/zh not_active Expired - Fee Related
- 2000-05-24 JP JP2001500731A patent/JP2003501019A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995034638A1 (fr) *	1994-06-14	1995-12-21	The Board Of Trustees Of Leland Stanford Junior University	Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques
WO1999042564A2 (fr) *	1998-02-20	1999-08-26	The Rockefeller University	Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUSSO ET AL, BLOOD, 92(10) SUPPL.1, PART 1-2, 1998 P. 667A *

Also Published As

Publication number	Publication date
IL146777A0 (en)	2002-07-25
CN1360628A (zh)	2002-07-24
HK1047131A1 (zh)	2003-02-07
WO2000073415A2 (fr)	2000-12-07
AU5215900A (en)	2000-12-18
JP2003501019A (ja)	2003-01-14
WO2000073415A3 (fr)	2001-03-01
EP1185626A2 (fr)	2002-03-13
KR20020013563A (ko)	2002-02-20
CA2375349A1 (fr)	2000-12-07
CN1187442C (zh)	2005-02-02
ITMI991180A1 (it)	2000-11-28
IT1312570B1 (it)	2002-04-22

Publication	Publication Date	Title
Latouche et al.	2000	Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells
Rouard et al.	2000	Adenoviral transduction of human ‘clinical grade’immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity
Märten et al.	2003	Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma
AU2008243221B2 (en)	2011-10-27	Process for producing cytotoxic lymphocyte
Chinnasamy et al.	2000	Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors
Diao et al.	1999	Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro
CA2536492C (fr)	2013-10-08	Procede de production de lymphocytes cytotoxiques
AU4183100A (en)	2000-10-16	(in vitro) induction of antigen-specific t-cells using dendritic cell-tumor cellor dendritic cell-viral cell derived immunogens
Yang et al.	1997	Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells
AU772703B2 (en)	2004-05-06	A method for the transfer of antigens to dendritic cells
CA3205129A1 (fr)	2022-07-28	Cellules presentatrices d'antigene modifiees
CN109810197A (zh)	2019-05-28	用于高效扩增nk的人工抗原递呈细胞及其构建方法
CN116970562B (zh)	2024-01-02	一种抗原特异性t细胞的制备方法及其在免疫治疗中的应用
Akagi et al.	2001	CD3+ CD56+ CD8+ cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients
CN111166876A (zh)	2020-05-19	一种免疫增强剂组合和编码核酸及其应用
US5672493A (en)	1997-09-30	De novo induction of cells exhibiting characteristics of macrophages utilizing feline sarcoma virus
Keoshkerian	2002	Gene therapy in acute non-lymphoblastic leukaemia
US20040253720A1 (en)	2004-12-16	Use of the cd24 marker gene for the selection of keratinocyte stem cells transformed by exogenous sequences
Nordon et al.	1999	Summary and Future Directions
Metzger et al.	2002	Induction of a T helper cell response against the tumor-associated antigen HER2 using monocyte-derived dendritic cells

Legal Events

Date	Code	Title	Description
2004-09-02	FGA	Letters patent sealed or granted (standard patent)